Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, T-Cell, Peripheral × Salvage Therapy × 90 days × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Brain Neoplasms 1

Interventions

Cyclophosphamide 3 Biopsy 3 Azacitidine 3 Prednisone 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Doxorubicin 2 tislelizumab 1 tazemetostat 1 sodium-iodide symporter 1 selinexor 1 ruxolitinib 1 romidepsin 1 relatlimab 1 pembrolizumab 1 ivarmacitinib 1 gemcitabine-oxaliplatin regimen 1 fludarabine 1 etoposide phosphate 1 duvelisib 1 decitabine and cedazuridine drug combination 1 cemiplimab 1 cc-486 1 belinostat 1 X-Rays 1 Vincristine 1 Spinal Puncture 1 Specimen Handling 1 Salvage Therapy 1 Prednisolone 1 Photons 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07470996 2026-03-13

T-START-NR

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡